Hypertension

a global pandemic

1 billion

Number of people with hypertension worldwide3

1 billion

Number of people with hypertension worldwide3

$150 billion

Economic burden of hypertension the US2

High Mortality

Single largest contributor to death worldwide1

High Mortality

Single largest contributor to death worldwide1

High Risk

Dramatically increases risk of heart attack, stroke, heart failure and kidney failure3

High Risk

Dramatically increases risk of heart attack, stroke, heart failure and kidney failure3

Drug Resistance

Blood pressure targets are achieved and controlled in only half of all treated hypertensives4

Drug Resistance

Blood pressure targets are achieved and controlled in only half of all treated hypertensives4

The future of renal denervation for uncontrolled hypertension

– By Shawn Moaddeb
The first SYMPLICITY HTN trials generated enthusiasm for catheter-based treatment of hypertension resistant to pharmacotherapy. However, when the treatment arm of SYMPLICITY HTN-3 failed to show significantly lower systolic blood pressure than the control group, some industry observers concluded that the door had been closed on renal denervation. Despite this surprisingly negative result, most industry participants (manufacturers, physicians, etc.) remain optimistic about the future of renal denervation. The sponsor of SYMPLICITY has redesigned its product and refined its trial protocol, while other major medical device manufacturers continue with their own product development in the area. Key physician opinion leaders continue to view renal denervation as a potential hypertension treatment, not least as all clinical trials to date have shown the procedure to be safe. There are several factors driving this enthusiasm…

Read More

Further reading

American Heart Association
World Health Organization
Cardiovascular Research Foundation (CRF)
EuroPcr

Sources

[1] WHO – Global Health Observatory (GHO) data, accessed Feb 2 2016
[2] Heidenreich PA, Trogdon JG, Khavjou O, Butler J, et al. Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association. Circulation. 2011;123:933-944
[3] Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-23.
[4] Chobanian et al. Hypertension. 2003; 42(6):1206-1252.

Development of our state-of-the-art solution continues to progress.

To receive updates, please subscribe to our mailing list.

Development of our state-of-the-art solution continues to progress.

To receive updates, please subscribe to our mailing list.

Renal Dynamics’ third-generation renal denervation system has received CE mark and is approved for sale in Europe. The system is not currently approved for use in the USA.

© 2020 Renal Dynamics - All Rights Reserved Terms of Use